10 reasons why to use citicoline Review article
Article Sidebar
Published:
Mar 31, 2022
Keywords:
citicoline, effectiveness, safety
Main Article Content
Abstract
Citicoline is an endogenous compound and play important role in cellular metabolism. It may be helpful in treatment of stroke, Parkinson and Alzheimer disease, glaucoma, after head injury etc. The safety of citicoline was confirmed in many studies.
Article Details
How to Cite
Kopka , M., & Sochacki , R. (2022). 10 reasons why to use citicoline. Medycyna Faktow (J EBM), 15(1(54), 64-69. https://doi.org/10.24292/01.MF.0122.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Jasielski P, Piędel F, Piwek M et al. Application of Citicoline in Neurological Disorders: A Systematic Review. Nutrients. 2020; 12(10): 3113.
2. Iulia C, Ruxandra T, Costin L-B et al. Citicoline – A neuroprotector with proven effects on glaucomatous disease. Romanian J Ophthalmol. 2017; 61: 152-8.
3. Herskovits AZ, Guarente LP. SIRT1 in Neurodevelopment and Brain Senescence. Neuron. 2014; 81: 471-83.
4. Secades JJ. Citicoline: Pharmacological and clinical review, 2016 update. Rev De Neurol. 2016; 63: S1-S73.
5. Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S et al. Influence of citicoline on citalopram-induced antidepressant activity in depressive- like symptoms in male mice. Physiol Behav. 2018; 195: 151-7.
6. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003; 73: 308-15.
7. Gandolfi SA, Marchini G, Caporossi A et al. Cytidine 50-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12: 793.
8. Medline C, Warach S, Pettigrew L. Citicoline Monograph. Altern Med Rev. 2008; 13: 50-7.
9. Mehta A, Mahale R, Buddaraju K et al. Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful? J Neurosci Rural Pr. 2019; 10: 576-81.
10. Das SK, Ghosh S, Nath T et. al. The effect of citicoline on stroke: A comparative study from the Eastern part of India. Neurol India. 2015; 63: 697-701.
11. Leon-Jimenez C, Chiquete E, Cantu C et al. Citicoline for acute ischemic stroke in Mexican hospitals: A retrospective postmarketing analysis. Methods Find. Exp Clin Pharm. 2010; 32: 325-30.
12. Álvarez-Sabín J, Santamarina E, Maisterra O et al. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. Int J Mol Sci. 2016; 17: 390.
13. Iranmanesh F, Vakilian A. Efficiency of Citicoline in Increasing Muscular Strength of Patients with Nontraumatic Cerebral Hemorrhage: A Double- blind Randomized Clinical Trial. J Stroke Cereb Dis. 2008; 17: 153-5.
14. Seifaddini R, Hamze MA, Iranmanesh F et al. The Effects of Citicoline on Cerebrovascular Hemodynamic Status in Ischemic Stroke Patients. J Kerman Univ Med Sci. 2017; 24: 480-6.
15. Secades JJ, Alvarez-Sabín J, Castillo J et. al. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cereb Dis. 2016; 25: 1984-96.
16. Dávalos A, Castillo J, Álvarez-Sabín J et al. Oral citicoline in acute ischemic stroke. Stroke. 2002; 33: 2850-7.
17. Overgaard K, Meden P. Citicoline – the first effective neuroprotectant to be combined with thrombolysis in acute ischemic stroke? J Neurol Sci. 2006; 247(2): 119-20.
18. Dávalos A, Alvarez-Sabín J, Castillo J et al. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo- controlled study (ICTUS trial). Lancet. 2012; 380: 349-57.
19. Mitta M, Goel D, Bansal KK et. al. Edaravone – citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India. 2012; 60: 36-8.
20. Spiers PA, Myers D, Hochanadel GS et al. Citicoline Improves Verbal Memory in Aging. Arch Neurol. 1996; 53: 441-8.
21. McGlade E, Locatelli A, Hardy A et al. Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. J Food Nutr Sci. 2012; 6(3): 769-73.
22. McGlade E, Agoston AM, DiMuzio J et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord. 2019; 23(2): 121-34.
23. Gareri P, Cotroneo AM, Castagna A et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013; 8: 131-7.
24. Cohen RA, Browndyke JN, Moser DJ et al. Long-Term Citicoline (Cytidine Diphosphate Choline) Use in Patients with Vascular Dementia: Neuroimaging and Neuropsychological Outcomes. Cereb Dis. 2003; 16: 199-204.
25. Cotroneo AM, Castagna A, Putignano S et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013; 8: 131-7.
26. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005; (2): CD000269. http://doi.org/10.1002/14651858.CD000269.pub3.
27. Caamano J, Gomez MJ, Franco A et al. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol. 1994; 16: 211-8.
28. Alvarez XA, Mouzo R, Pichel V et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999; 21(9): 633-44.
29. Piamonte BLC, Espiritu AI, Anlacan VMM. Effects of Citicoline as an Adjunct Treatment for Alzheimer’s Disease: A Systematic Review. J Alzheimers Dis. 2020; 76(2): 725-32.
30. Castagna A, Cotroneo AM, Ruotolo G et al. The CITIRIVAD Study. Citicoline plus rivastigmine in elderly patients affected with dementia study. Clin Drug Investig. 2016; 36: 1059-65.
31. Gareri P, Castagna A, Cotroneo AM et al. The Citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis. 2017; 56: 557-65.
32. Trimmel H, Majdan M, Wodak A et al. Citicoline in Severe Traumatic Brain Injury: Indications for Improved Outcome: A Retrospective Matched Pair Analysis From 14 Austrian Trauma Centers. Wien Klin Wochenschr. 2018; 130: 37-44.
33. Shokouhi G, Haghjoo AG, Sattarnezhad N et al. Effects of Citicoline on Level of Consciousness, SerumLevel of Fetuin-A andMatrix Gla-Protein (MGP) in Trauma Patients with Diffuse Axonal Injury (DAI) and GCS _ 8. Turk. J Trauma Emerg Surg. 2014; 20: 410-6.
34. Zafonte RD, Bagiella E, Ansel BM et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012; 308: 1993-2000.
35. Secades JJ. Citicoline for the Treatment of Head Injury: A Systematic Review and Meta-analysis of Controlled Clinical Trials. J Trauma Treat. 2014; 4: 227.
36. Ruggieri S, Zamponi A, Casacchia M et al. Effetti terapeutici della citicolina (citidin difosfo colina) nella sindrome parkinsoniana. Clinica Terapeutica. 1976; 78(6): 515-25.
37. Agnoli A, Ruggieri S, Denaro A et al. New strategies in the management of Parkinson’s disease:A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology. 1982; 8: 289-96.
38. Eberhardt R, Birbamer G, Gerstenbrand F et al. Citicoline in the treatment of Parkinson’s disease. Clin Ther. 1990; 12: 489-95.
39. Que DS, Jamora RDG. Citicoline as Adjuvant Therapy in Parkinson’s Disease: A Systematic Review. Clin Ther. 2021; 43(1): e19-e31.
40. Parisi V, Coppola G, Centofanti M et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008; 173: 541-54.
41. Ottobelli L, Manni GL, Centofanti M et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica. 2013; 229: 219-26.
42. Gandolfi S, Marchini G, Caporossi A et al. Cytidine 5’-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12(3): 793.
43. Jefferis JM, Connor AJ, Clarke MP. Amblyopia. BMJ. 2015; 351: h5811.
44. Campos EC, Schiavi C, Benedetti P et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol. 1995; 233(5): 307-12.
45. Porciatti V, Schiavi C, Benedetti P et al. Cytidine-50-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res. 1998; 7(2): 141-8.
46. Vagge A, Ferro Desideri L, Traverso CE. An update on pharmacological treatment options for amblyopia. Int Ophthalmol. 2020; 40(12): 3591-7.
47. Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs. 2014; 28: 185-93.
48. Lozano-Fernandez R. Efficacy and safety of oral CDP-choline. Drug Res. 1983; 33: 1073-80.
49. Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Meth Findings Experim Clin Pharmacol. 2009; 31: 171-6.
50. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995; 56: 637-60.
51. Wilson JM, Levey AI, Bergeron C et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996; 40: 428-39.
52. Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse. 2014; 40(4): 262-8.
53. Renshaw PF, Daniels S, Lundahl LH et al. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine- dependent subjects: a preliminary report. Psychopharmacology (Berl). 1999; 142: 132-8.
54. Licata SC, Penetar DM, Ravichandran C et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addiction Med. 2011; 5: 57-64.
55. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. 2007; 27: 498-502.
2. Iulia C, Ruxandra T, Costin L-B et al. Citicoline – A neuroprotector with proven effects on glaucomatous disease. Romanian J Ophthalmol. 2017; 61: 152-8.
3. Herskovits AZ, Guarente LP. SIRT1 in Neurodevelopment and Brain Senescence. Neuron. 2014; 81: 471-83.
4. Secades JJ. Citicoline: Pharmacological and clinical review, 2016 update. Rev De Neurol. 2016; 63: S1-S73.
5. Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S et al. Influence of citicoline on citalopram-induced antidepressant activity in depressive- like symptoms in male mice. Physiol Behav. 2018; 195: 151-7.
6. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003; 73: 308-15.
7. Gandolfi SA, Marchini G, Caporossi A et al. Cytidine 50-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12: 793.
8. Medline C, Warach S, Pettigrew L. Citicoline Monograph. Altern Med Rev. 2008; 13: 50-7.
9. Mehta A, Mahale R, Buddaraju K et al. Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful? J Neurosci Rural Pr. 2019; 10: 576-81.
10. Das SK, Ghosh S, Nath T et. al. The effect of citicoline on stroke: A comparative study from the Eastern part of India. Neurol India. 2015; 63: 697-701.
11. Leon-Jimenez C, Chiquete E, Cantu C et al. Citicoline for acute ischemic stroke in Mexican hospitals: A retrospective postmarketing analysis. Methods Find. Exp Clin Pharm. 2010; 32: 325-30.
12. Álvarez-Sabín J, Santamarina E, Maisterra O et al. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. Int J Mol Sci. 2016; 17: 390.
13. Iranmanesh F, Vakilian A. Efficiency of Citicoline in Increasing Muscular Strength of Patients with Nontraumatic Cerebral Hemorrhage: A Double- blind Randomized Clinical Trial. J Stroke Cereb Dis. 2008; 17: 153-5.
14. Seifaddini R, Hamze MA, Iranmanesh F et al. The Effects of Citicoline on Cerebrovascular Hemodynamic Status in Ischemic Stroke Patients. J Kerman Univ Med Sci. 2017; 24: 480-6.
15. Secades JJ, Alvarez-Sabín J, Castillo J et. al. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cereb Dis. 2016; 25: 1984-96.
16. Dávalos A, Castillo J, Álvarez-Sabín J et al. Oral citicoline in acute ischemic stroke. Stroke. 2002; 33: 2850-7.
17. Overgaard K, Meden P. Citicoline – the first effective neuroprotectant to be combined with thrombolysis in acute ischemic stroke? J Neurol Sci. 2006; 247(2): 119-20.
18. Dávalos A, Alvarez-Sabín J, Castillo J et al. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo- controlled study (ICTUS trial). Lancet. 2012; 380: 349-57.
19. Mitta M, Goel D, Bansal KK et. al. Edaravone – citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India. 2012; 60: 36-8.
20. Spiers PA, Myers D, Hochanadel GS et al. Citicoline Improves Verbal Memory in Aging. Arch Neurol. 1996; 53: 441-8.
21. McGlade E, Locatelli A, Hardy A et al. Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. J Food Nutr Sci. 2012; 6(3): 769-73.
22. McGlade E, Agoston AM, DiMuzio J et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord. 2019; 23(2): 121-34.
23. Gareri P, Cotroneo AM, Castagna A et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013; 8: 131-7.
24. Cohen RA, Browndyke JN, Moser DJ et al. Long-Term Citicoline (Cytidine Diphosphate Choline) Use in Patients with Vascular Dementia: Neuroimaging and Neuropsychological Outcomes. Cereb Dis. 2003; 16: 199-204.
25. Cotroneo AM, Castagna A, Putignano S et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013; 8: 131-7.
26. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005; (2): CD000269. http://doi.org/10.1002/14651858.CD000269.pub3.
27. Caamano J, Gomez MJ, Franco A et al. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol. 1994; 16: 211-8.
28. Alvarez XA, Mouzo R, Pichel V et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999; 21(9): 633-44.
29. Piamonte BLC, Espiritu AI, Anlacan VMM. Effects of Citicoline as an Adjunct Treatment for Alzheimer’s Disease: A Systematic Review. J Alzheimers Dis. 2020; 76(2): 725-32.
30. Castagna A, Cotroneo AM, Ruotolo G et al. The CITIRIVAD Study. Citicoline plus rivastigmine in elderly patients affected with dementia study. Clin Drug Investig. 2016; 36: 1059-65.
31. Gareri P, Castagna A, Cotroneo AM et al. The Citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis. 2017; 56: 557-65.
32. Trimmel H, Majdan M, Wodak A et al. Citicoline in Severe Traumatic Brain Injury: Indications for Improved Outcome: A Retrospective Matched Pair Analysis From 14 Austrian Trauma Centers. Wien Klin Wochenschr. 2018; 130: 37-44.
33. Shokouhi G, Haghjoo AG, Sattarnezhad N et al. Effects of Citicoline on Level of Consciousness, SerumLevel of Fetuin-A andMatrix Gla-Protein (MGP) in Trauma Patients with Diffuse Axonal Injury (DAI) and GCS _ 8. Turk. J Trauma Emerg Surg. 2014; 20: 410-6.
34. Zafonte RD, Bagiella E, Ansel BM et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012; 308: 1993-2000.
35. Secades JJ. Citicoline for the Treatment of Head Injury: A Systematic Review and Meta-analysis of Controlled Clinical Trials. J Trauma Treat. 2014; 4: 227.
36. Ruggieri S, Zamponi A, Casacchia M et al. Effetti terapeutici della citicolina (citidin difosfo colina) nella sindrome parkinsoniana. Clinica Terapeutica. 1976; 78(6): 515-25.
37. Agnoli A, Ruggieri S, Denaro A et al. New strategies in the management of Parkinson’s disease:A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology. 1982; 8: 289-96.
38. Eberhardt R, Birbamer G, Gerstenbrand F et al. Citicoline in the treatment of Parkinson’s disease. Clin Ther. 1990; 12: 489-95.
39. Que DS, Jamora RDG. Citicoline as Adjuvant Therapy in Parkinson’s Disease: A Systematic Review. Clin Ther. 2021; 43(1): e19-e31.
40. Parisi V, Coppola G, Centofanti M et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008; 173: 541-54.
41. Ottobelli L, Manni GL, Centofanti M et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica. 2013; 229: 219-26.
42. Gandolfi S, Marchini G, Caporossi A et al. Cytidine 5’-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12(3): 793.
43. Jefferis JM, Connor AJ, Clarke MP. Amblyopia. BMJ. 2015; 351: h5811.
44. Campos EC, Schiavi C, Benedetti P et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol. 1995; 233(5): 307-12.
45. Porciatti V, Schiavi C, Benedetti P et al. Cytidine-50-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res. 1998; 7(2): 141-8.
46. Vagge A, Ferro Desideri L, Traverso CE. An update on pharmacological treatment options for amblyopia. Int Ophthalmol. 2020; 40(12): 3591-7.
47. Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs. 2014; 28: 185-93.
48. Lozano-Fernandez R. Efficacy and safety of oral CDP-choline. Drug Res. 1983; 33: 1073-80.
49. Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Meth Findings Experim Clin Pharmacol. 2009; 31: 171-6.
50. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995; 56: 637-60.
51. Wilson JM, Levey AI, Bergeron C et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996; 40: 428-39.
52. Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse. 2014; 40(4): 262-8.
53. Renshaw PF, Daniels S, Lundahl LH et al. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine- dependent subjects: a preliminary report. Psychopharmacology (Berl). 1999; 142: 132-8.
54. Licata SC, Penetar DM, Ravichandran C et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addiction Med. 2011; 5: 57-64.
55. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. 2007; 27: 498-502.